Topics

Gliomas | Treatment | Targeted therapy | BRAF/MEK inhibitors

Home > Publications > Topics > Gliomas > Treatment > Targeted therapy > BRAF/MEK inhibitors

Khoury JE, Wehbe S, Attieh F, Boutros M, Kesrouani C, Kourie HR.
A critical review of RAF inhibitors in BRAF-mutated glioma treatment.
Pharmacogenomics. 2024 Jun 3:1-13. doi: 10.1080/14622416.2024.2355859. PMID: 38884947. Review˰ ˍ

Bazer DA, Kolchinski A, Bush NAO, Clarke JL, Bagley SJ, Schreck KC.
No drug holidays in BRAF^V600E glioma patients: An argument for dose reduction of targeted therapies.
Neurooncol Pract. 2024 May 24;11(5):660-664. doi: 10.1093/nop/npae046. PMID: 39279775. Case report˰ ˍ

Perreault S, Geurts M, Mahdi J, Schreck KC, Preusser M, Wen PY, Lim-Fat MJ, Werner JM.
Point/counterpoint: Upfront BRAF inhibition for adult BRAF-mutant high-grade gliomas.
Neuro Oncol. 2025 Jul 26:noaf164. doi: 10.1093/neuonc/noaf164. PMID: 40717628. Perspective. ˍ